Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JBI-778 in Brain Metastasis, Leptomeningeal Disease, or High Grade Recurrent Glioma
NCT07751744Phase 2Not yet recruiting
- Sponsor
- Jubilant Therapeutics Inc.
- Start
- Apr 2028
- Primary completion
- Mar 2030
01
Overview
A Phase 2 trial of JBI-778 in brain metastasis (BM), leptomeningeal disease (LMD), glioma, sponsored by Jubilant Therapeutics Inc.. Planned start Apr 2028; status: not yet recruiting.
02
Drugs
JBI-778
03
Conditions
brain metastasis (BM)leptomeningeal disease (LMD)glioma
Beyond the preview
Go deeper on NCT07751744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07751744.